26 September, 2018

The (LL) Quality Trademark is certified proof that products have been independently tested and developed by Lumir Lab.

Lumir Lab offers a variety of solutions to ensure the safety and quality of medical cannabis products. Lumir Lab’s (LL) Quality Trademark is certified proof that any product have been independently tested and developed by Lumir Lab in order to meet the applicable published standard. Each test performed is conducted in cohesion with exceedingly strict quality control protocols. We analyze each product to see if it complies with relevant requirements to determine if it, in fact, meets the highest standards. Only then do we grant certification of approval to indicate compliance and qualification. Any product bearing the (LL) Quality Trademark is determined to have met the requirements of prescribed product safety standards. Lumir Lab offers the validity of product compliance by publishing the results of each and every product that has been tested through our labs.

7 June, 2018

Meet Gynica – Lumir’s Lab first R&D collaboration.

Gynica focuses on clinically proven cannabis-based solutions in the field of women’s health. Gynica develops optimal therapeutic results, based on innovative technology and understanding of the pharmacological effects of different cannabinoids and compounds, targeted to specific diseases. Led by Professor Moshe Hod, an international leader in the field of women’s health, serving as the President of the European Association of Perinatal Medicine (EAPM) and Professor of Gynecology at the Tel Aviv University Faculty of Medicine.


The female reproductive system contains the most endocannabinoid receptors in the human body, after the brain.


Gynica have absolute confidence in cannabinoids as an innovative lead to positively affect different gynecological disorders. Current treatments either fall short or are inefficient; Gynica offers a multisite intervention method to treat illnesses such as endometriosis, menstrual cramps, and more. To date, only insufficient pain treatments are available on the market, yielding very limited effectiveness in the alleviation of women’s suffering. An ideal drug treatment would eliminate endometriotic lesions, prevent recurrence, reduce pain, all while having no negative impact on the ovulation cycle. Advanced therapeutics capable of accomplishing these needs are required, and Gynica has the tools to analyze and conceive positive solutions.